Alleviating the Metabolic Side Effects of Antipsychotic Medications

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2012

Conditions
Schizophrenia
Interventions
DRUG

Moxonidine

"Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks."

DRUG

Placebo

"To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group."

DRUG

Moxonidine

"Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks."

DRUG

Placebo

"To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group."

Trial Locations (4)

Unknown

Ballarat Health Service Psychiatric Services, Ballarat

Monash Medical Centre - Monash Health, Clayton

Alfred and Baker Medical Unit - Alfred Hospital, Melbourne

Baker IDI Heart & Diabetes Institute, Melbourne

All Listed Sponsors
collaborator

The Alfred

OTHER

collaborator

Monash Medical Centre

OTHER

collaborator

Ballarat Health Services

OTHER

lead

Baker Heart and Diabetes Institute

OTHER

NCT01567124 - Alleviating the Metabolic Side Effects of Antipsychotic Medications | Biotech Hunter | Biotech Hunter